EV Suseong "Salvation Signs Contract to Supply 10.8 Million Covixil Units to Daechun Bio in China"

[Asia Economy Reporter Jang Hyowon] EV Suseong announced on the 4th that its affiliate Salvacion has signed a contract to supply Covixil to Anhui Dacheng Bioengineering Co., Ltd. (Dacheng Bio) in China.

Under this contract, Salvacion will supply 10.8 million units of Covixil to Dacheng Bio. Covixil is a nasal spray for COVID-19 prevention developed independently by Salvacion. It was the first in the world to receive government agency approval in the UK and 15 Caribbean Community countries.

The company stated, "Due to the global worsening of COVID-19 infections, following the large-scale supply contract with Dacheng Bio, we expect additional major global orders to follow," and added, "Negotiations for additional contracts with major Chinese companies are also in the final stages."

They continued, "The large-scale supply contract for Covixil will drive the performance growth of both Salvacion and EV Suseong."

Covixil has been verified to neutralize over 99% of respiratory viruses including COVID-19 and influenza. It was developed with research and development support from the U.S. National Cancer Institute (NCI) and has been officially introduced through platforms such as Nature (Springer Nature) and the World Health Organization (WHO) global open access platform.

Meanwhile, Covixil is actively sold nationwide in the United States through Walmart’s online and offline stores. It has also become a bestseller on online shopping malls. In particular, with the recent emergence of variant viruses such as XBB.1.5, there was even a temporary product shortage, the company explained.